Physician profile
Andres E Reyes
NPI 1124312905
$1,136.21
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2021: $48.83 · 2022: $133 · 2024: $39.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $255.25 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $216.13 | 2019 | |
| Melinta Therapeutics, LLC | $132.96 | 2022 | |
| Genentech USA, INC. | $115.44 | 2019 | |
| Astellas Pharma US INC | $88.55 | 2019 | |
| Pfizer INC. | $72.59 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.39 | 2019 | |
| Sandoz INC. | $38.49 | 2019 | |
| Abbott Laboratories | $35.21 | 2019 | |
| Advanced Respiratory, INC | $30.61 | 2019 | |
| Gilead Sciences, INC. | $23.23 | 2019 | |
| Abiomed | $20.79 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $18.84 | 2024 | Breztri |
| Mylan Specialty L.P. | $16.67 | 2019 | |
| Glaxosmithkline, LLC. | $15.07 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.